U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Pentosan polysulfate sodium (brand name ELMIRON) is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects and is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. The mechanism of action of pentosan polysulfate sodium in interstitial cystitis is not known but was discovered, that it t binds Fibroblast growth factors (FGFs) as well as other heparin-binding growth factors.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ELMIRON

Approved Use

ELMIRON® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
68.7 ng/mL
400 mg/m² 3 times / day multiple, oral
dose: 400 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PENTOSAN POLYSULFATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
462 ng/mL
400 mg/m² 3 times / day multiple, oral
dose: 400 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PENTOSAN POLYSULFATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
250 ng × eq/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOSAN POLYSULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
358 ng × eq/mL
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOSAN POLYSULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
987.5 ng × h/mL
400 mg/m² 3 times / day multiple, oral
dose: 400 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PENTOSAN POLYSULFATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6660 ng × h/mL
400 mg/m² 3 times / day multiple, oral
dose: 400 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PENTOSAN POLYSULFATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
21 ng × eq × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOSAN POLYSULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
33.8 ng × eq × h/mL
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOSAN POLYSULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
26.5 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOSAN POLYSULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
19.5 h
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOSAN POLYSULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1500 mg single, oral
Highest studied dose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: FASTED
Sources:
400 mg/m2 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg/m2, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
DLT: Proctitis...
Disc. AE: Diarrhea, GI bleeding...
Other AEs: Hematuria, Gastritis...
Dose limiting toxicities:
Proctitis (grade 3-4, 18%)
AEs leading to
discontinuation/dose reduction:
Diarrhea (grade 4, 27%)
GI bleeding (grade 1-2, 27%)
Other AEs:
Hematuria (grade 1, 9%)
Gastritis (4.5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Gastritis 4.5%
400 mg/m2 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg/m2, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Hematuria grade 1, 9%
400 mg/m2 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg/m2, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
GI bleeding grade 1-2, 27%
Disc. AE
400 mg/m2 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg/m2, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Proctitis grade 3-4, 18%
DLT, Disc. AE
400 mg/m2 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg/m2, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Diarrhea grade 4, 27%
Disc. AE
400 mg/m2 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg/m2, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.
2010-12
Sulfated dextrans enhance in vitro amplification of bovine spongiform encephalopathy PrP(Sc) and enable ultrasensitive detection of bovine PrP(Sc).
2010-10-04
The role of hypoxia in 2-butoxyethanol-induced hemangiosarcoma.
2010-01
Early identification of interstitial cystitis may avoid unnecessary hysterectomy.
2009-10-02
Patients with chronic pelvic pain: endometriosis or interstitial cystitis/painful bladder syndrome?
2007-09-01
Ketamine-associated ulcerative cystitis: a new clinical entity.
2007-05
Pentosan polysulfate (Elmiron): in vitro effects on prostate cancer cells regarding cell growth and vascular endothelial growth factor production.
2006-11
Molecular size affects urine excretion of pentosan polysulfate.
2006-03
Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis.
2006
Metabolism of [3H]pentosan polysulfate sodium (PPS) in healthy human volunteers.
2005-08
Cyclophosphamide induced hemorrhagic cystitis successfully treated with pentosanpolysulphate.
2005-01
NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).
2004-05
Toxicity and carcinogenicity of Elmiron in F344/N rats and B6C3F1 mice following 2 years of gavage administration.
2003-12
Lysosomal-storage disorder induced by elmiron following 90-days gavage administration in rats and mice.
2002-04-13
Effect of pentosan polysulfate therapy on intravesical potassium sensitivity.
2002-03
Osteoarthritis, genetic and molecular mechanisms.
2002
Pentosan polysulfate decreases proliferation and extracellular matrix deposition by vascular smooth muscle cells isolated from failed hemodialysis access grafts.
2000-08
Pentosan induced cerebral sagittal sinus thrombosis: a variant of heparin induced thrombocytopenia.
1998-12
Pentosan polysulfate-induced thrombocytopenia: a case diagnosed with an ELISA test used for heparin-induced thrombocytopenia.
1996-07
Effect of sodium pentosan polysulphate on the thrombogenicity of prothrombin complex concentrates.
1992-07-01
Trans-repressor activity of nuclear glycosaminoglycans on Fos and Jun/AP-1 oncoprotein-mediated transcription.
1992-01
Thrombocytopenia with or without thrombosis after pentosan polysulfate treatment.
1990-11-01
[Myocardial infarction and massive biventricular thrombosis during thrombocytopenia induced by pentosan polysulfate and heparin].
1990-01
[Disseminated coronary thrombosis and thrombopenia induced by pentosan polysulfate].
1988-07
[Myocardial infarct complicating thrombopenia induced by pentosan polysulfate].
1988-04
[Thrombopenia and fatal intracerebral hemorrhage caused by pentosan polysulfate].
1988-01-30
Patents

Sample Use Guides

The recommended dose of ELMIRON® (pentosan polysulfate sodium, capsules) is 300 mg/day taken as one 100 mg capsule orally three times daily. The capsules should be taken with water at least 1 hour before meals or 2 hours after meals. Patients receiving ELMIRON® should be reassessed after 3 months. If improvement has not occurred and if limiting adverse events are not present, ELMIRON® may be continued for another 3 months.
Route of Administration: Oral
Effect of pentosan polysulfate (PPS) on p38, ERK1/2 and JNK MAPK activation was studied. Canine chondrocytes were plated onto 6-well culture plates in serum free DMEM for 24 hr. Cells were pre-treated with 100 µg/ml of PPS for 1 hr and then incubated with 10 ng/ml of recombinant human (rh) IL-1β for 5, 15, 30, 60 or 240 min. It was shown, that phosphorylation of p38 and ERK were inhibited by 100 mg/ml of PPS, while JNK remained constant despite PPS pretreatment prior to rhIL-1β stimulation. Effect of PPS on NF-κB translocation induced by rhIL- 1β: Under control conditions, a diffuse cytoplasmic staining was seen and the average percentage of NF-κB positive nuclei cells was 9.5%. On the other hand, 78.2% of chondrocytes incubated with rhIL- 1β had a nuclear staining pattern, indicating NF-κB nuclear translocation. Preincubation with 10 and 100 µg/ml PPS reduced NF-κB translocation rate.
Substance Class Polymer
Created
by admin
on Tue Apr 01 20:35:54 GMT 2025
Edited
by admin
on Tue Apr 01 20:35:54 GMT 2025
Record UNII
914032762Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENTOSAN POLYSULFATE SODIUM
INN   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
CARTROPHEN
Preferred Name English
SP54
Code English
(4-O-METHYL-.ALPHA.-D-GLUCURONO)-(1->2)-(1->4)-.BETA.-D-XYLOPYRANAN, HYDROGEN SULPHATE, SODIUM SALT
Common Name English
SP-54
Code English
FIBREZYM
Brand Name English
THROMBOCID
Brand Name English
LYSOSAN
Brand Name English
PENTOSAN POLYSULPHATE SODIUM
Common Name English
PENTOSAN POLYSULFATE SODIUM [IARC]
Common Name English
FIBRASE
Brand Name English
SODIUM PENTOSAN POLYSULPHATE
Common Name English
NSC-626201
Code English
PENTOSAN POLYSULFATE SODIUM [ORANGE BOOK]
Common Name English
(4-O-METHYL-.ALPHA.-D-GLUCURONO-.BETA.-D-XYLAN, HYDROGEN SULPHATE, SODIUM SALT
Common Name English
PENTOSAN POLYSULFATE SODIUM [VANDF]
Common Name English
(4-O-METHYL-.ALPHA.-D-GLUCURONO-.BETA.-D-XYLAN, HYDROGEN SULFATE, SODIUM SALT
Common Name English
PENTOSAN POLYSULFATE SODIUM [MART.]
Common Name English
Pentosan polysulfate sodium [WHO-DD]
Common Name English
pentosan polysulfate sodium [INN]
Common Name English
PZ68
Code English
HEPARINOID (PENTOSAN POLYSULFATE SODIUM SALT)
Common Name English
PENTOSAN POLYSULFATE SODIUM SALT [MI]
Common Name English
PENTOSAN POLYSULFATE SODIUM [USAN]
Common Name English
ELMIRON
Brand Name English
(4-O-METHYL-.ALPHA.-D-GLUCURONO)-(1->2)-(1->4)-.BETA.-D-XYLOPYRANAN, HYDROGEN SULFATE, SODIUM SALT
Common Name English
PZ-68
Code English
Classification Tree Code System Code
NCI_THESAURUS C263
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
FDA ORPHAN DRUG 352311
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
WHO-VATC QG04BX15
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
EU-Orphan Drug EU/3/14/1411
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
WHO-ATC G04BX15
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
WHO-ATC C05BA04
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
WHO-VATC QC05BA04
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
FDA ORPHAN DRUG 1784
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
FDA ORPHAN DRUG 251607
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
FDA ORPHAN DRUG 458614
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
WHO-VATC QM01AX90
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C946
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
DRUG BANK
DBSALT000991
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
EVMPD
SUB14081MIG
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
ALTERNATIVE
SMS_ID
100000090271
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
FDA UNII
914032762Y
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
MERCK INDEX
m8517
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID1025229
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
CAS
140207-93-8
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
NSC
626201
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201516
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
USAN
Z-41
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
CAS
37319-17-8
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
ALTERNATIVE
EVMPD
SUB14801MIG
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
INN
6311
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
HSDB
37319-17-8
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
RXCUI
134413
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY RxNorm
DAILYMED
914032762Y
Created by admin on Tue Apr 01 20:35:54 GMT 2025 , Edited by admin on Tue Apr 01 20:35:54 GMT 2025
PRIMARY
Display Structure of PENTOSAN POLYSULFATE SODIUM
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:WEIGHT AVERAGE CHEMICAL